浸润性微乳头状癌与浸润性导管癌免疫组化及临床病理特征的比较

目的:研究乳腺浸润性微乳头状癌(IMPC)的临床病理特点及与 ER、PR、c-erbB-2和E-cadherin的表达关系.方法:回顾性分析608例乳腺癌患者临床资料,筛选IMPC,观察其临床病理特点,SP法检测ER、PR、c-erbB-2及E-cadherin的表达,并与浸润性导管癌(IDC)比较.结果:IMPC在乳腺癌中的发生率为4.9%(30/608),组织形态表现为缺乏纤维血管轴心的微乳头或管泡状细胞簇被纤细的胶原纤维间质分隔,两者之间有一个透明、扩张的腔隙,淋巴结转移灶癌组织保留着微乳头状的生长方式.IMPC淋巴结转移90.0%显著高于IDC的53.3%,肿瘤最大径＞2 cm者83.3%较IDC的53.3%明显多.IMPC与IDC的ER、PR、c-erbB-2表达率分别为46.7%和56.7%,53.3%和43.3%,40.0%和60.0%,两者差异无统计学意义.IMPC的E-cadherin表达为90.0%,明显高于IDC组的63.3%,且主要表达于肿瘤细胞间连接面及管腔内的细胞膜,而微乳头朝向间质面的细胞膜则表达减弱或消失.结论:IMPC是乳腺癌中的少见类型,与IDC相比,具有较高的淋巴结转移率,其高转移潜能可能与微乳头状的生长方式及E-cadherin高表达及特定的表达方式有关,而与ER、PR、c-erbB-2表达无关.     

散发性乳腺浸润性导管癌中BRCA1 表达及临床意义*

目的:研究散发性乳腺浸润性导管癌（invasive ductal carcinoma,IDC）（breastcancer 1 BRCA1）基因的表达及其与其临床病理特征之间的关系。方法:采用免疫组化SP三步法检测67例乳腺浸润性导管癌,53例乳腺腺病患者的石蜡标本BRCA1 的表达,从病理科的档案提取患者的年龄,肿物大小,淋巴结转移情况,ER,PR,Her-2 表达结果,分析BRCA1 的表达和患者的年龄,肿物大小,淋巴结转移情况及ER,PR,Her-2 表达的关系。结果:BRCA1蛋白在IDC 组织表达率56.7%（38/67）,癌旁组织表达率80.0%（36/45）,乳腺腺病组织表达率92.5%（49/53）。 阳性细胞定位除细胞核外,也见于胞浆。IDC 癌组织与癌旁组织、乳腺腺病组织比较,BRCA1 阳性表达率均下降,均有显著性差异（P<0.05）。 BRCA1 的表达与淋巴结转移呈负相关（r=-0.137,P<0.05）,与ER、PR、Her-2 的表达均呈负相关（r 值分别为-0.439,-0.250,-0.363,P<0.05）,与年龄、肿物大小无明显相关性（P>0.05）。 结论:BRCA1 蛋白可作为估计乳腺癌生物学行为和预后的潜在指标。      

散发性乳腺浸润性导管癌中BROA1表达及临床意义

目的：研究散发性乳腺浸润性导管癌（invasive ductal carcinoma,IDC）（breast cancer 1 BRCA1）基因的表达及其与其临床病理特征之间的关系。方法：采用免疫组化sP三步法检泖167例乳腺浸润性导管癌,53例乳腺腺病患者的石蜡标本BRCA1的表达。从病理科的档案提取患者的年龄,肿物大小,淋巴结转移情况,ER,PR,Her-2表达结果,分析BRCA1的表达和患者的年龄,肿物大小,淋巴结转移情况及ER,PR,Her－2表达的关系。结果：BRCA1蛋白在IDC组织表达率56．7％（38／67）,癌旁组织表达率80．0％（36／45）,乳腺腺病组织表达率92．5％（49,53）。阳性细胞定位除细胞核外,也见于胞浆。IDC癌组织与癌旁组织、乳腺腺病组织比较,BRCA1阳性表达率均下降,均有显著性差异（P〈0．05）。BRCAI的表达与淋巴结转移呈负相关（r=-0．137,P〈0．05）,与ER、PR、Her－2的表达均呈负相关（r值分别为－0．439,－0．250,－0．363,P〈0．05）,与年龄、肿物大小无明显相关性（P〉0,05）。结论：BRCA1蛋白可作为估计乳腺癌生物学行为和预后的潜在指标。     

PDGF-BB 在乳腺浸润性导管癌中的表达及其临床意义

目的:探讨PDGF-BB在乳腺浸润性导管癌中的表达及其与临床病理特征之间的关系。方法:收集2015年6月至2017年8月新疆医科大学第一附属医院经病理证实的乳腺浸润性导管癌80例,采用免疫组化方法检测癌组织及癌旁组织PDGF-BB表达状况,并分析其与临床病理特征关系。结果:乳腺浸润性导管癌组织中PDGF-BB表达明显高于癌旁组织（57.50% vs 13.75%,P<0.05）;PDGF-BB表达与淋巴结转移（P<0.05）和较高的pTNM分期有关（P<0.05）;而与年龄、月经状态、肿瘤直径、PR、ER、HER-2、有无术后复发转移等临床病理特征无关（P>0.05）。结论:PDGF-BB在乳腺浸润性导管癌的发生及进展中起重要作用,其预后价值仍需进一步评价。     

乳腺浸润性导管癌预后相关因素分析

目的:探讨乳腺浸润性导管癌预后相关因素.方法: 收集130例乳腺浸润性导管癌资料,回顾性分析其临床特征、病理分化程度、复发转移情况、激素受体状况、人类表皮生长因子受体2的表达、临床治疗及生存情况.结果: c-erbB-2表达在ER、PR阳性组低于ER、PR阴性组(P<0.01),ER表达在PR阳性组高于PR阴性组(P<0.01);中、低分化与高分化相比,在淋巴结的转移、肿瘤的转移或复发、临床分期、肿块的大小上,均有统计学差异(P<0.05);单因素分析结果显示,激素受体状况、人类表皮生长因子受体2表达、病理分化程度、淋巴结状况、肿瘤转移或复发、临床分期、肿瘤大小、T分期、N分期、辅助化疗等11个因素与预后相关;多因素分析结果显示:ER状况、病理分化程度、淋巴结状况、临床分期是乳腺浸润性导管癌患者预后的独立影响因素.结论: 对乳腺浸润性导管癌,早期发现并针对病理分化程度及激素受体水平的适当治疗是提高生存期的关键.     

雌激素调节蛋白PS2乳腺浸润性导管癌表达及其临床意义

[目的]探讨雌激素调节蛋白(PS2)在乳腺浸润性导管癌中的表达及其与临床病理因素间的关系。[方法]采用免疫组化方法检测155例乳腺浸润性导管癌中ER、PR和PS2的表达。[结果]全组PS2表达阳性率38.1%。在ER阳性和阴性病例中,PS2阳性率分别为48.6%和29.4%(χ2=5.977,P<0.05);在PR阳性和阴性组中,PS2阳性率分别为50.8%和28.9%(χ2=7.664,P<0.01)。PS2的表达与病人年龄、月经状况、肿瘤大小无关(P>0.05);而与腋淋巴结状况(P<0.001)、临床分期(P<0.05)有关。此外,PS2的表达在民族间也存在一定差异,但无统计学意义。[结论]乳腺浸润性导管癌中PS2的表达与ER、PR呈正相关关系,并与腋淋巴结状况和临床分期有关。PS2可以作为预测乳腺癌预后的一项重要指标。     

乳腺导管／小叶混合型癌的临床病理分析

目的 比较分析乳腺导管/小叶混合型癌（mixed ductal/lobular carcinoma）与乳腺浸润性导管癌（invasive ductal carcinoma,IDC）的临床病理特征.方法 回顾性分析2009年7月至2012年12月沈阳军区总医院普外科收治的35例乳腺导管/小叶混合型癌及86例IDC的临床病理资料,比较二者的临床病理特征.计数资料采用χ2检验及Fisher确切概率法,等级资料采用非参数检验,多因素分析采用二分类非条件Logistic回归分析.结果 单因素分析显示ER、PR阳性表达率及E-cadherin阴性表达率混合型癌组显著高于IDC组（χ2=4.169、8.860、12.392;P=0.041、0.003、0.000）,多因素回归分析提示PR和E-cadherin是混合型癌与IDC的独立危险因素[Exp（B）=2.957,95%CI=1.250～6.991,P=0.014;Exp（B）=0.255,95%CI=0.104～0.623;P=0.003].但发病年龄、月经情况、腋窝淋巴结转移、HER-2与Ki67阳性表达、TNM分期两组差异均无统计学意义（χ2=1.442、0.979、0.455、0.010、2.364,P=0.230、0.323、0.500、0.920、0.124;Z=-0.197,P=0.844）.结论 乳腺导管/小叶混合型癌是兼有IDC与浸润性小叶癌临床病理特征但却独立的一种类型.     

乳腺浸润性微乳头状癌组织中Twist和E-cadherin的表达及其意义

目的:探讨乳腺浸润性微乳头状癌（IMPC）组织中Twist和E-cadherin的表达及其意义。方法:应用免疫组织化学方法检测56例乳腺IMPC和100例乳腺浸润性导管癌（IDC）组织中Twist和E-cadherin的表达,分析其与乳腺IMPC临床病理特征之间关系及其相互关系。结果:乳腺IMPC脉管侵犯和淋巴结转移阳性率分别为91.1%（51/56）和82.1%（46/56）,明显高于IDC组的43.0%（43/100）和51.0%（51/100）,差异有统计学意义（P＜0.05);而年龄及肿块大小乳腺IMPC与IDC组比较,差异无统计学意义（P＞0.05）。乳腺IMPC和IDC组织中Twist表达阳性率分别为76.8%（43/56）和61.0%（61/100）,差异有统计学意义（P＜0.05）,而E-cadherin的阳性表达率分别为73.2%（41/56）和68.0%（68/100）,差异无统计学意义（P＞0.05)。Twist在乳腺IMPC组织中阳性表达与脉管侵犯、淋巴结转移及ER表达相关,差异有统计学意义（P＜0.05）;而与年龄、民族、肿块大小、组织学类型、微乳头比例、PR及Her-2表达无关,差异均无统计学意义（P＞0.05）。E-cadherin在乳腺IMPC组织中阳性表达与淋巴结转移和ER表达相关,差异有统计学意义（P＜0.05）;而与年龄、民族、肿块大小、组织学类型、微乳头比例、脉管侵犯、PR及Her-2表达无关,差异均无统计学意义（P＞0.05）。Spearman 相关性分析表明,Twist与E-cadherin在乳腺IMPC组织中的表达呈负相关（P＜0.05）。结论:乳腺IMPC组织中Twist与E-cadherin均高表达,且其表达对肿瘤细胞的上皮间质转化（EMT）有重要意义,促进了肿瘤细胞的侵袭和转移,对乳腺IMPC的发生、发展及判断预后有指导作用。     

乳腺浸润性导管癌中Clusterin蛋白表达及其与临床病理特征的关系

[目的]探讨细胞凋亡抑制因子Clusterin在乳腺浸润性导管癌组织中的表达及其与临床病理因素的关系。[方法]应用免疫组化SP法检测70例乳腺浸润性导管癌、20例乳腺增生和10例乳腺癌旁组织标本中Clusterin的表达情况。[结果]Clusterin在乳腺癌旁正常组织、乳腺增生及乳腺浸润性导管癌组织中的阳性表达率分别为0、20.0%及71.4%,乳腺浸润性导管癌组织中的Clusterin表达水平明显高于乳腺增生及乳腺癌旁正常组织(P<0.05)。Clusterin蛋白在乳腺浸润性导管癌中的表达与临床分期、组织学分级及淋巴结转移情况有关(P<0.05),而与患者年龄、肿瘤大小无关(P>0.05)。在乳腺浸润性导管癌组织中Clusterin与ER、PR的表达呈负相关(P<0.05)。[结论]Clusterin可能在乳腺癌的发生发展中发挥重要促进作用,可望成为乳腺浸润性导管癌诊断中的标志物及新的治疗靶点。     

ER、PR和PS2在乳腺浸润性导管癌中的表达及其临床意义

目的探讨ER、PR和PS2在乳腺浸润性导管癌中的表达及其与临床、病理各因素间的关系。方法采用免疫细胞化学方法检测155例乳腺浸润性导管癌中ER、PR和Ps：的表达。结果全组PS2表达阳性率为38．1％，与ER、PR表达符合率分别为60．6％、62．6％。在ER阳性和阴性病例中，PS2阳性率分别为48．6％和29．4％（X^2=5．977，P〈0．05）；在PR阳性和阴性组中，PS2阳性率分别为50．8％和28．9％（X^2=7．664，P〈0．01），均呈正相关关系。PS2的表达与患者年龄、月经状况、肿瘤大小无关（P〉0．05），与腋窝淋巴结状况（P〈0．01）、临床分期（P〈0．05）有关。结论乳腺浸润性导管癌中PS2的表达与ER、PR呈正相关关系，并与腋窝淋巴结状况和临床分期有关，提示PS2可能对指导乳腺癌临床内分泌治疗具有重要意义。     

Expression of DDR1 and DVL1 in Invasive Ductal and Lobular Breast Carcinoma does not Correlate with Histological Type,Grade and Hormone Receptor Status

Background: Invasive ductal (IDC) and lobular (ILC) carcinomas are the common histological types of breastcarcinoma which are difficult to distinguish when poorly differentiated. Discoidin domain receptor (DDR1) andDrosophila dishevelled protein (DVL1) were recently suggested to differentiate IDC from ILC. Objectives: Toassess the expression of DDR1 and DVL1 and their association with histological type, grading and hormonalstatus of IDC and ILC. Materials and Methods: This cross sectional study was conducted on IDC and ILC breasttumours. Tumours were immunohistochemically stained for (DDR1) and (DVL1) as well as estrogen receptor(ER), progesterone receptor (PR) and C-erbB2 receptor. Demographic data including age and ethnicity wereobtained from patient records. Results: A total of 51 cases (30 IDCs and 21 ILCs) were assessed. DDR1 andDVL1 expression was not significantly associated with histological type (p=0.57 and p=0.66 respectively). Therewas no association between DDR1 and DVL1 expression and tumour grade (p=0.32 and p=1.00 respectively),ER (p=0.62 and 0.50 respectively), PR (p=0.38 and p=0.63 respectively) and C-erbB2 expression (p=0.19 andp=0.33 respectively) in IDC. There was no association between DDR1 and DVL1 expression and tumour grade(p=0.52 and p=0.33 respectively), ER (p=0.06 and p=0.76 respectively), PR (p=0.61 and p=0.43 respectively) andC-erbB2 expression (p=0.58 and p=0.76 respectively) in ILC. Conclusions: This study revealed that DDR1 andDVL1 are present in both IDC and ILC regardless of the tumour differentiation. More studies are needed toassess the potential of these two proteins in distinguishing IDC from ILC in breast tumours.     

16例乳腺化生性癌的临床病理分析及EMT相关指标的表达

目的:研究乳腺化生性癌（metaplastic carcinoma of the breast,MBC）的临床病理特征,并探讨上皮间质转化(epithelial-mesenchymal transformation,EMT)指标E-钙黏蛋白（E-cadherin）与波形蛋白（Vimentin）在MBC和乳腺浸润性导管癌（invasive ductal carcinoma of the breast,IDC）中的差异性表达。方法:回顾性分析16例MBC患者的临床病理资料;同时选取与上述MBC临床病理特征匹配的16例IDC作为对照组。采用免疫组化SP法检测上述两组病例癌组织中ER、PR、HER-2、Ki-67、E-cadherin以及Vimentin的表达情况。结果:16例MBC中4例为纯鳞状细胞癌,4例为鳞状细胞癌伴有非特殊性浸润性癌,7例为梭形细胞癌,1例为混合型;患者中位发病年龄51岁,中位最大直径3.8 cm,淋巴结阳性率43.8%;ER/PR阳性率为0,HER-2阳性率为18.8%,13例为三阴性乳腺癌。E-cadherin在MBC组中的正常表达率低于IDC组（0% vs 37.5%,P<0.05）;Vimentin在MBC组中表达增加,强于IDC组（P<0.05）。结论:MBC是一种罕见的特殊类型的浸润性乳腺癌,形态学异质性明显,激素受体低表达,分子分型以三阴性癌为主;另外MBC中EMT程度明显高于IDC,故其预后较IDC差。     

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution

Background

Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC.

Methods

We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10–69, 70–89, and ≥90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status.

Results

In total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50–69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC.

Conclusion

Patients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.

     

E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.

In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin expression and whether the gene mutations present in ILC are already present in LCIS is not known. We report here that E-cadherin expression is absent in six cases of LCIS and present in 150 cases of ductal carcinoma in situ (DCIS), both without an adjacent invasive component. Furthermore, using mutation analysis, we could demonstrate the presence of the same truncating mutations and loss of heterozygosity (LOH) of the wild-type E-cadherin in the LCIS component and in the adjacent ILC. Our results indicate that E-cadherin is a very early target gene in lobular breast carcinogenesis and plays a tumour-suppressive role, additional to the previously suggested invasion-suppressive role.     

胃癌及胃癌前病变中 E-cadherin及其 相关蛋白的表达

目的：探讨 E-cadherin、α -catenin、β -catenin和γ -catenin与胃癌发生及胃癌生物学行为的关系。方法：用免疫组织化学方法检测 E-cadherin及α -catenin、β -catenin、γ -catenin在 43例胃癌, 22例胃癌前病变及 10例正常胃粘膜中的表达。结果：在胃癌前病变中 E-cadherin,α -catenin、β -catenin、γ -catenin的异常表达率分别为 22.7％、 22.7％、 18.2％、 27.3％,分别与胃癌 E-cadherin（ 53.5％）,α -catenin（ 55.8％）、β -catenin（ 51.2％）的异常表达率相比差异有显著性（ P<0.05）。进展期胃癌异常表达率较早期胃癌高,除γ catenin外差异均有显著意义（ P< 0.05或 P< 0.01）。低分化胃癌 E cadherin的异常表达率较高,胃癌浸润到浆膜外及伴随淋巴结转移时 E cadherin、β catenin的异常表达率升高（ P< 0.05或 P< 0.01）。 76.7％的胃癌及 50.0％的胃癌前病变 E cadherin系统中至少有一项表达异常,二者差异有显著性（ P< 0.05）,且至少有一项为表达异常病人的淋巴结转移率明显高于无蛋白异常表达者（ P< 0.01）。结论： E cadherin及部分相关蛋白的表达异常与胃癌的分化程度、临床分期、浸润深度及淋巴结转移密切相关, E cadherin系统在由胃不典型增生转化为胃癌的过程中起作用,联合检测 E cadherin及α catenin、β catenin、γ catenin可提高检测结果的参考价值。     

Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast

Purpose

The purpose of this study was to assess the incidence of invasive lobular carcinoma (ILC) and to compare the clinicopathological features and treatment results after breast conserving surgery (BCS) followed by radiotherapy between ILC and invasive ductal carcinoma (IDC).

Methods

A total of 1,071 patients who underwent BCS followed by radiotherapy were included in the study. Medical records and pathological reports were retrospectively reviewed.

Results

The incidence of ILC was 5.2% (n=56). Bilateral breast cancer, lower nuclear grade, and hormone receptor-positive breast cancer were more frequent in patients with ILC than in those with IDC. There were no cases of lymphovascular invasion or the basal-like subtype in patients with ILC. There were no statistically significant differences in patterns of failure or treatment outcomes between patients with ILC and those with IDC. The development of metachronous contralateral breast cancer was more frequent in patients with IDC (n=27). Only one patient with ILC developed contralateral breast cancer, with a case of ductal carcinoma in situ.

Conclusion

The incidence of ILC was slightly higher in our study than in previous Korean studies, but was lower than the incidences reported in Western studies. The differences we observed in clinico pathological features between ILC and IDC were similar to those described elsewhere in the literature. Although there were no statistically significant differences, there was a trend toward better disease-specific survival and disease-free survival rates in patients with ILC than in those with IDC.     

E-钙黏附蛋白和p120-连环素蛋白在乳腺浸润性小叶癌和导管癌中的表达差异及意义

目的 比较乳腺浸润性小叶癌(ILC)和浸润性导管癌(IDC)的临床病理学特征,探讨E-钙黏附蛋白(E-cadherin)和p120-连环素蛋白(p120-catenin)在ILC和IDC中的表达差异及意义.方法 中国医学科学院肿瘤医院1999年1月至2006年12月共收治ILC 123例,2000年收治IDC 334例.运用组织微阵列及免疫组织化学染色技术,对123例ILC和334例IDC患者的组织蜡块进行切片,并进行E-cadherin和p120-catenin表达的检测,同时对患者进行随访.结果 ILC和IDC患者的5年无瘤生存率(DFS)分别为61.8%和83.7%(P＜0.001),5年总生存率(OS)分别为81.7%和79.1%(P=0.055).在36例ILC和221例IDC患者中,E-cadherin表达缺失率分别为55.6%(20/36)和20.4%(45/221,P＜0.001),p120-catenin胞浆表达率分别为66.7%(24/36)和16.3%(36/221,P＜0.001).在ILC患者中,p120-catenin胞浆表达与E-cadherin表达缺失相关(P=0.002).ILC和IDC患者中,p120-catenin胞浆表达合并E-cadherin表达缺失的比率分别为55.6%(20/36)和4.1%(9/221,P＜0.001).结论 ILC具有不同于IDC的临床病理学特点及预后特征,E-cadherin和p120-catenin的检测有助于ILC和IDC的鉴别诊断.     

E-cadherinP120ctn在乳腺癌中的表达及意义

  目的  探讨E-钙黏蛋白(E-cadherin, E-cad)、P120连环蛋白(P120ctn)在乳腺浸润性导管癌(IDC)和浸润性小叶癌(ILC)中的表达及其鉴别诊断意义。  方法  收集解放军第113医院2007年12月至2012年5月间有完整随访资料的浸润性导管癌60例、浸润性小叶癌48例及混合性癌20例。采用免疫组织化学S-P法检测E-cad及P120的表达。  结果  E-cad在IDC和ILC中的阳性率分别为85%(51/60)和0, 其差异有统计学意义(P < 0.01);P120在IDC中阳性率为100%, 且均为细胞膜着色, 而在ILC中阳性率亦为100%, 但均为胞浆着色。E-cad和P120联合使用将20例混合癌确诊为IDC 16例及ILC 4例。IDC中E-cad的表达水平与肿瘤分期无关, 与淋巴结转移有关(P < 0.05)。  结论  E-cad和P120联合使用可以鉴别光镜下易混淆的IDC和ILC, 使组织分型更准确, 建议应用于乳腺癌的常规免疫组织化学检测。E-cad的表达水平与淋巴结转移有关。      

E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma.

Expression of the calcium-dependent cell-cell adhesion molecule E-cadherin has been examined in 187 primary breast carcinomas using an immunohistochemical technique. The pattern and extent of reactivity has been correlated with clinicopathological data including tumour type, grade and lymph node status and with other prognostic parameters including oestrogen receptor (ER) status, expression of c-erbB-2, pS2 protein and epidermal growth factor receptor (EGFR). Two patterns of E-cadherin staining were observed in carcinomas, membrane reactivity and a diffuse cytoplasmic staining. A marked difference in expression of E-cadherin was observed between infiltrating lobular carcinomas (ILC) and infiltrating ductal carcinomas (IDC), the former showing complete loss of membrane staining, whereas 93% of IDC retained some level of expression. In IDC reactivity was not related to tumour grade but there was a significant association between reduced membrane levels of E-cadherin and the presence of lymph node metastasis, and a highly significant correlation between the presence of cytoplasmic E-cadherin and metastasis. A significant relationship was also demonstrated between reduced E-cadherin reactivity and expression of EGFR. These findings emphasise the complexity of control of E-cadherin in breast carcinomas and provide evidence of a link between membrane signalling pathways and modulation of E-cadherin expression.     

乳腺癌肿瘤组织不同部位雌孕激素受体的表达

目的 探讨乳腺浸润性导管癌肿瘤组织中不同部位雌、孕激素受体表达情况.方法 收集32例手术切除乳腺浸润性导管癌肿瘤标本,于每例肿瘤标本4个不同部位取材,用免疫组化方法检测各部位雌、孕激素受体表达情况.结果 肿瘤组织不同部位雌、孕激素受体检测结果一致性好,最好Kappa值分别为0.789和0.810,最差Kappa值分别为...